Introduction
Unlike most other imaging techniques which noninvasively delineate cardiac anatomy and structure in often exquisite detail, which afford calculation of chamber volumes and their changes during cardiac systole and diastole and thus are suited for accurate analysis of global and regional ventricular function or which visualize or provide indices of coronary and tissue blood flow, positron emission tomography (PET) offers the unique capability of probing regional myocardial tissue function. The capabilities of PET include evaluation and quantification of substrate fluxes, substrate interactions and biochemical reaction rates, of blood flow and oxidative metabolism and of pre-and post-synaptic neuronal activity in myocardial regions of the human heart.
Clinical investigations with PET have focused thus far on coronary artery and on ischemic heart disease. Among numerous available and potentially useful positron emitting tracer substances, these studies have relied largely upon only a few tracers as for example of blood flow, fatty acid * Operated for the U.S. Department of Energy by the University of California under Contract #DE-AC03-76-SF00012. This work was supported in part by the Director of the Office of Energy Research, Office of Health and Environmental Research, by NIH Grants #HL 29845 and #HL 33177, and by an Investigative Group Award by the Greater Los Angeles Affiliate of the American Heart Association. metabolism and glucose utilization. Value and limitations of these tracers were established in animal experiments. For example, N-13 ammonia was employed as a tracer of blood flow [1, 2] , C-11 palmitate as a tracer of myocardial fatty acid metabolism [3] [4] [5] [6] and F-18 2-fluoro 2-deoxyglucose (FDG) as a tracer of exogenous glucose utilization [7, 8] . In addition to having provided new insights into the pathophysiology of human myocardial ischemia, these studies have also indicated the promise of PET for refining clinical diagnosis and patient care.
PET studies of metabolism in myocardial ischemia
Observations in in vitro experimental systems and in intact animals served as rationale for probing myocardial ischemia in humans with tracers of fatty acid and of glucose [9, 10] . These findings reported an impairment of oxidative metabolism, especially of fatty acid, and a transient increase in glycolytic flux early during the evolution of myocardial ischemia. Other studies suggested however that glycolytic flux could be maintained, provided inhibitory metabolites were removed by residual tissue blood flow [11] . Studies in dog experiments indicated that PET could indeed demonstrate enhanced glycolytic flux and impaired oxidation of fatty acid when C-11 palmitate and FDG were employed together with a tracer of blood flow [6, 12] . PET images and cardiac anatomy in the normal heart. Six contiguous cross-sectional image (each spaced apart by 9 mm) were obtained after intravenous injection of F-18 2-deoxyglucose (FDG) in a normal volunteer. The images are viewed from the subject's feet and are acquired from the base to the inferior wall of the left ventricle (top to bottom). RV = free right ventricular wall, A = anterior, L = lateral and IP = inferoposterior wall. S -interventricular septum. MV = mitral valve plane and aPM = anterior papillary muscle.
These initial animal experiments on P E T were confined to acute myocardial ischemia. Subsequent studies with F D G and PET in patients with ischemic heart disease demonstrated the existence of a similar metabolic pattern of enhanced glucose utilization even when clinical signs of ischemia were absent at the time of the study (Figs. i and 3. Glucose utilization in segments with reduced blood flow was found to be augmented either relative to normal myocardium or reltive to blood flow [13] [14] [15] . The latter was evaluated with N-13 ammonia. Although some patients reported episodes of mild angina during the PET study, suggesting that the observed metabolic abnormality might be attributable to acute ischemia, the majority of patients were without clinical signs of ischemia at the time of study or during the preceding 24 hours. This then raised the question whether this metabolic pattern was not unique to acute myocardial ischemia but also reflected a metabolic alteration that originated with a previous ischemic episode and therefore depicted the altered metabolic state of post-ischemic and presumably recovering myocardium. Persistence of augmented F D G uptake in myocardial segments that were hypoperfused during bicycle exercise [16] or in chronic dog experiments with reperfusion after a 3-hour coronary occlusion supported such possible explanation [17] . Fig. 3 . Myocardial blood flow and glucose utilization in a patient with ischemic heart disease. Regional myocardial blood flow is highly heterogeneous as seen on the left. It is preserved best in the anterior interventricular septum and the basal regions of the anterolateral wall and reduced most in the anterior wall and the posterior interventricular septum (arrows). Note however the preserved glucose utilization in these regions as seen by the relatively homogeneous glucose uptake on the right. In these regions, glucose utilization is increased relative to blood flow.
The prevalence of this metabolic abnormality in patients examined with P E T several weeks after an acute myocardial infarction lends additional support to this possibility [13] . Moreover, only segments with this metabolic abnormality on PET during the early post-infarction period improved function spontaneously over the following 8 to 10 weeks [18] .
A metabolic adaptation to chronically low or inadequate tissue oxygenation was considered as another possibility. Such adaptation may hinge on a precarious balance between demand and supply 201 of blood flow and thus, of oxygen. Theoretically, this adaptation may range from a regional shift from fatty acid to glucose oxidation in order to more efficiently use the already limited oxygen supply for ATP production to a complete impairment of oxidative metabolism, leaving anaerobic glycolysis as one of the last possible resources for ATP production. These metabolic processes however continue only if some residual tissue blood flow for substrate supply and, especially, for removal of inhibitory metabolites persists. Therefore, if blood flow declines further or if demand and production of inhibitory metabolites increases excessively, ischemia might then proceed to necrosis.
Adaptation to a chronically low tissue oxygen tension as a possible explanation of this metabolic pattern will be difficult to verify. It depends on a supply/demand imbalance that is constant or changes only within a relatively narrow range. For example, heart rate and blood pressure and thus, demand, constantly vary in response to changes in physical activity. Even mental activity as for example simple arithmatics, might raise demand or lower supply [19] . Therefore, a relatively constant imbalance as a prerequisite for the above assumption of an adaptation to a chronically low tissue oxygenation state is therefore unlikely to exist. Accordingly, this metabolic pattern may result from a combination of several factors. An adaptation to a chronically low oxygen tissue supply may further be modulated by transient ischemic insults, imposed by temporary increases in demand or decreases in supply, causing repeated ischemic insults, followed by metabolic recovery but interrupted by new and repeated ischemic episodes. An example for the latter possibility is the progressive deterioration and ultimate cessation of segmental function as a result of repeated transient coronary occlusions in dogs [20] .
Clinical relevance of segmentally enhanced glucose utilization: A sign of tissue viability
Elucidation of mechanisms accounting for the observed metabolic pattern on P E T is important for gaining new insights into the pathophysiology of human myocardial ischemia. However, from a clinician's point of view, the question whether this pattern reflects ischemically injured but viable and potentially salvageable myocardium is equally important. This pattern will subsequently be referred to as "mismatch". P E T reveals another pattern, where glucose utilization in a hypoperfused and functionally impaired segment is decreased in proportion to flow. This pattern will be referred to as "match" (Figs. 4 and 5) .
If metabolic studies on P E T do indeed descriminate between viable or reversibly injured and nonviable, irreversibly injured tissue, function in segments with "mismatches" would and in segments with "matches" would not be expected to improve after restoration of blood flow. Therefore, patients with segmental wall motion abnormalities were studied with P E T prior to coronary artery bypass surgery. Segmental function was evaluated before and 8 to 10 weeks after bypass surgery [14] . In 13 patients, there were 73 regions with impaired wall motion. Of these, 27 revealed "matches" and 46 "mismatches" on PET. Sixty-seven of these regions were adequately revascularized. Function improved after surgical revascularization in only 8% of regions with "matches" but in 85% of segments with "mismatches".
The functional outcome after surgical revascularization confirmed the hypothesis of metabolic activity as an accurate discriminator between reversible and irreversible tissue injury and of the pattern of "mismatch" being a sign of tissue viability. The findings further indicated that P E T predicted with an 88% accuracy the functional outcome after surgical revascularization.
The functional impairment associated with persistent although abnormal metabolic activity and its recovery after restoring blood flow calls to mind the recently proposed term of "hibernating myocardium" [21, 22] . Inadequate oxygen supply severely curtails production of high energy phosphates. In response, the myocyte presumably eliminates expenditure of energy into mechanical function as an energy saving measure. The residual energy is spent for sustaining "critical functions" as for example maintenance of transmembraneous Fig. 4 . Blood flow and exogenous glucose utilization in six contiguous cross-sectional images of the left ventricle in a patient with ischemic heart disease and impaired left ventricular function. Note the increased size of the left and right ventricular cavities as well as the enhanced uptake of 13NH3 in both lungs. Uptake of 13NH3 is also present in the liver as seen in planes 4 to 6. Regional myocardial blood flow is decreased in the anterior wall adjacent to the interventricular septum (arrows). The defect increases in size towards the more distal distribution of the left anterior descending coronary artery and is associated with a concordant decrease in glucose utilization (arrows) as seen on the images on the right. ion concentration gradients. Among several possible processes, anaerobic glycolysis apparently plays a key role. It is the latter which PET apparently identifies by the enhanced F D G uptake and thus augmented glucose utilization. The question is not whether but how much viability or "hibernating myocardium" is there in a given myocardial region for this will determine the anticipated magnitude of functional improvement after interventional restoration of blood flow. 
Role of PET in today's diagnostic armamentarium for identifying tissue viability
The ability of PET for identifying tissue viability and for distinguishing reversible from irreversible ischemic tissue injury compares favorably with that by widely employed alternate modalities [15] . For example, Q-waves on ECG, long considered as an index of transmural necrosis, have recently been foundto be far less specific [22, 23] . In fact, there is some evidence that Q-waves may be associated with only transient ischemia or Q-waves may resolve after surgical revascularization [22, 23] . An analysis of Q-wave regions for persistence of blood 203 flow and metabolic activity on PET indicated a general relationship between the absence of metabolic activity and Q-waves, yet there was viable tissue in a substantial number of Q-wave segments [15] . In fact, all Q-wave regions with "mismatches" on PET improved segmental wall motion after bypass surgery, whereas those with "matches" did not [14] . The severity of regional wall motion abnormalities similarly was unrelated to tissue viability [15] . Q-wave regions that were normal on PET had significantly better wall motion scores than those which were abnormal. However, the degree of wall motion impairment was equal in segments with "mismatches" (viable) and with "matches" (non-viable or scar tissue).
Evaluation of the relative distribution of regional myocardial blood flow at rest similarly failed to distinguish between reliably viable and non-viable myocardium [25] . Metabolic activity was consistently present when blood flow was reduced by less than 60% relative to normal myocardium. Conversely, when blood flow was decreased by more than 80%, metabolic activity was no longer seen on PET. Importantly, intermediate ranges of flow reductions, between 60% and 80%, were associated with both viable and non-viable tissue. Thus, while segmental blood flow reductions can aid in determining presence or absence of viable myocardium, their value is limited for flow reductions in the intermediate range.
Stress T1-201 scintigraphy currently plays a key role for identifying tissue viability. Immediate post-exercise defects that resolve either completely or partially on delayed imaging are considered regions of viability, whereas defects that persist unchanged or are fixed are thought to reflect nonviable myocardium or scar tissue. Follow-up studies before and after therapeutic interventions as for example angioplasty or coronary artery bypass surgery recently pointed out limitations of this approach. For example, 12 of 16 fixed defects completely normalized on stress T1-201 scintigraphy after angioplasty [26] . Similarly, 19 of 42 fixed defects became entirely normal on stress T1-201 scintigraphy after surgical revascularization [27] . Correlative studies between planar T1-201 stress scintigraphy and PET generally confirmed the va-lidity of the stress T1-201 scintigraphic approach. For example, complete defect resolution was consistently associated on PET with normal or ischemic myocardium [28] . Generally, myocardial regions were viable on PET when their immediate post-exercise defects recovered either completely or partially. However, in regions with fixed defects, only 42% were by PET criteria truly irreversibly injured or exhibited scar formation, whereas the remaining 58% of fixed defects were either normal or metabolically ischemic. Thus, while stress T1-201 scintigraphy is useful for identifying tissue viability, its predictive accuracy is limited when defects are fixed. It is in this area where PET is more accurate than T1-201 scintigraphy in determining presence and absence of tissue viability.
In summary, while some of the currently and more widely used techniques are useful for determining tissue viability, their accuracy appears however limited. PET with its ability to detect residual or persistent though abnormal metabolic activity appears to exceed the accuracy of these techniques by defining better the absence or presence of tissue viability.
Evaluation of fatty acid metabolism in myocardial ischemia
The study of myocardial ischemia with PET has not been confined to studies with only FDG nor, as will be mentioned later, have PET studies been confined to myocardial ischemia. A number of clinical investigations employed C-11 palmitate to the study of myocardial ischemia. Recent myocardial infarctions typically exhibit segmentally reduced uptak e of C-11 palmitate. The extent of these segmental reductions has been found to correlate with infarct size [29, 30] . Other studies again have employed C-11 palmitate in patients with coronary artery disease at rest and, auring mild acute myocardial ischemia induced by moderate atrial pacing [31] . Tissue kinetics of C-11 palmitate at rest were normal in myocardial territories supplied by diseased coronary arteries. Pacing induced in territories subtended by normal and stenosed coronary arteries changes in the tissue kinetics of C-11 palmitate that were consistent with an increase in fatty acid oxidation in response to increased cardiac work. However, these changes were attenuated in regions supplied by stenosed coronary arteries, suggesting an inadequate increase in fatty acid oxidation. Interestingly, in only 50% of these segments was the attenuated response in C-11 palmitate tissue kinetics associated with other evidence of ischemia as for example development of new although subtle wall motion abnormalities on 2D echocardiography. The absence of signs of ischemia in the remaining 50% of patients raised questions as to he precision of echocardiography for detection of only subtle wall motion abnormalities or, conversely, whether a compensatory shift from fatty acid to glucose oxidation in these segments accounted for maintaining wall motion normal. If the latter explanation can be proved, these findings suggest that even very mild states of myocardial ischemia could be detected noninvasively with tracers of myocardial metabolism.
A role of PET in clinical cardiology
From the above discussion of clinical investigations with PET, several clinical conditions emerge that are likely to benefit from studies on PET. Not only is PET likely to identify or detect disease, but also aid in characterizing its extent and severity, or to be of predictive value and thus, impact clinical decision making as well as to be useful for early assessment of salutory effects of treatment. [16] and, more recently, Krivokapich et al. [32] in our laboratory have observed segmentally enhanced FDG uptake in myocardial regions that were. hypoperfused during supine or semi-erect bicycle exercise. In addition to implying greater reliance on glucose utilization relative to fatty acid oxidation as shown by Grover-McKay et at. [31] and possibly to some extent on anaerobic glycolysis, these studies suggest further that stress induced metabolic alterations do not necessarily resolve immediately but may persist for some time. It would seem reasonable to assume that the severity of the metabolic abnormality might be related 'to the degree of stress induced ischemia and, moreover, that the rate at which this metabolic abnormality resolves might prove useful for grading the severity of stress induced ischemia.
Stress induced ischemia. Camici and collaborators
Metabolic studies might equally be useful within the concept of "critical" coronary stenosis. For example, tracers of blood flow indicate only a segmentally attenuated response in blood flow to stress without proving definitively that ischemia occurs also. Whether an inadequate flow increase also causes ischemia could then be demonstrated with markers of metabolism. Thus, mild coronary stenosis could be evaluated not only for their hemodynamic significance but also whether they produce ischemia and at what level of exercise ischemia occurs. The approach would also aid in defining the efficacy of pharmacologic therapy as for example with nitrates, beta-blocking agents or calcium channel antagonists.
Chronic ischemic heart d&ease. As pointed out earlier, severely hypokinetic or akinetic segments with decreased blood flow frequently reveal on PET enhanced FDG uptake. This pattern identifies tissue viability more accurately than other currently employed techniques. When surgical revascularization or angioplasty is considered, PET predicts with an 88% accuracy whether segmental function will or will not improve. Metabolic studies with PET have been particularly useful in patients with increased risk for surgical revascularization, for example when left ventricular function is markedly redued. Preliminary findings indicate that there is a relationship between the fraction of myocardium that is still viable and the post-surgical improvement in global left ventricular function. It is especially the patient with fixed T1-201 defects where PET clearly distinguishes between tissue viability and scar tissue. The low signal intensity on T1-201 scintigrams and severely hypokinetic or akinetic segments often precludes adequate evaluation of possible redistribution, whereas the positive signal on PET/FDG studies more clearly identifies ischemic but viable tissue.
Acute myocardial infarction. The time required for
205 PET studies will likely preclude its use prior to implementation of therapy during the acute phase. During the early post-infarction period, "infarct" segments frequently continue to be metabolically active and, thus, to remain viable for some time. [18] . Augmented FDG uptake in about 50% of hypoperfused "infarct" segments 40 to 50 hours after onset of acute symptoms implies the presence of ischemically injured but viable and potentially viable myocardium in infarct regions. While function in metabolically inactive "infarct" segments ("matches") remains unchanged over the first 1 to 2 months post-infarction, function improves spontaneously in about half of the segments that are metabolically active during the early post-infarction period. Function in the other half of segments that are metabolically active early after infarction however fails to recover. Preliminary studies suggest progression of ischemia to necrosis in such segments. Thus, these two different functional outcomes suggest that different mechanisms might account for the segmentally enhanced FDG uptake. In segments with spontaneous improvement of function, an initial fall in blood flow might be followed by reperfusion through either collaterals or recanalization of the infarct vessel. Metabolic activity resumes and recovers followed by a return of function. On the other hand, in segments without improvement in function, some residual blood flow might initially persist at a critically low level and account for the observed metabolic activity. As blood fails to increase or becomes even more compromised, metabolic activity declines until necrosis ensues.
From these considerations, several therapeutic strategies emerge after "infarct" regions have been studied on PET. First, "infarct" regions without metabolic activity are unlikely to benefit from therapeutic interventions and should be considered necrotic. Second, segments that are metabolically active during the early post-infarction period and in which function recovers spontaneously would not require aggressive therapeutic treatment. Third, it is those segments in which metabolic activity is likely to disappear over time or which fail to improve function would benefit most from aggressive management. Restoration of blood flow to the lat-ter type of infarct regions should lead to salvage of injured but viable myocardium. However, reliable criteria that distinguish between the two latter types of metabolically active regions are still lack= ing and need to be established. One such criterion might be blood flow which should be higher in segments with spontaneous improvement in function.
Persistence of metabolic activity in infarct segments was most frequently associated with some residual antegrade blood flow through the infarct vessel when studied 10 to 15 days after the acute event [33] . This confirms the earlier advanced hypothesis that some flow is needed if metabolic processes for energy production are to be maintained so that tissue viability can be preserved. It appears also consistent with the recent suggestion that early coronary thrombolysis restores some blood flow and thus might be critical for maintaining tissue viable. After thrombolysis, PET could therefore establish the presence of viable myocardium and aid in deciding on use of additional measures as for example angioplasty or coronary bypass surgery.
PET after therapeutic interventions. Findings in ani-
mal experiments suggest that augmented glucose utilization early after reperfusion signifies tissue recovery long before a measureable improvement in regional function occurs [34] . It has been well established that functional improvement even after only short periods of ischemia is slow. Thus, transient ischemic episodes may lead to an impairment of segmental function that persists for considerable time periods. Assessment of segmental function is therefore limited for determining salutory effects of therapeutic interventions. Similarly, restoration of blood flow per se as determined by angiography or T1-201 scintigraphy does not necessarily prove that tissue has been salvaged. It appears therefore that PET studies with metabolic markers are most accurate and useful for predicting very early subsequent tissue outcome and the effects of therapeutic interventions [34] .
Summary and conclusions
Positron emission tomography and tracers of blood flow and of metabolism offer a most unique capability: The noninvasive study of regional myocardial metabolism and its derangements as a result of regional or global myocardial disease. Research with PET not only has confirmed the existence of metabolic fluxes and reactions as established previously through highly invasive or even destructive investigational techniques but has provided new insights into pathophysiologic processes, especially in ischemic and post-ischemic myocardium. From these investigations in both animal experiments and in humans, observations have emerged which indicate a place for PET in clinical cardiology. PET is likely to contribute to detection of disease, to characterizing its extent and severity as well as to decide upon the most appropriate therapeutic strategy and assessing its results. It is recognized that many of these observations with clinical implications await confirmation through larger clinical trials, follow-up studies as well as independent confirmation.
Besides exploring ischemic heart disease, PET is equally suitable for examinig substrate fluxes and interactions in other disorders as for example in intrinsic myocardial disease like primary and secondary cardiomyopathies [34] [35] [36] [37] . While derangements of metabolism in these disorders may be an expression of the consequences of the disease process or its underlying mechanisms itself, findings on PET will allow formulation of new hypotheses on disease mechanisms that conversely can then be tested.
In addition to F-18 2-deoxyglucose and C-11 palmitate, the number of tracers for substrate metabolism is likely to increase. An example is C-11 acetate currently intensely investigated as a tool for measuring overall myocardial oxidative metabolism [38] [39] [40] . Others as for example C-11 labeled short chain fatty acids are on the horizon. The study of cardiac receptors is similarly possible [41, 42] : Thus, a set of tools will soon be available for dissection of entire metabolic pathways and for determination of rate limiting steps in health and disease and to more clearly define specific defects in biochemical reaction steps that critically contribute to or even ae the specific cause of disease.
